Transmedics Group Inc

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TransMedics reports stellar Q4 earnings, eyes growth amid operational challenges

TransMedics Group Inc delivered strong financial performance in Q4 2022, driven by robust revenue growth and strategic investments in infrastructure.
While facing margin pressure and operational challenges, the company's focus on innovation and expansion positions it well for future growth and market leadership.
With a clear roadmap for 2023 and a solid cash position, TransMedics is poised to navigate challenges, capitalize on opportunities, and drive sustainable value creation.

Transmedics reports stellar Q1 results, anticipates growth challenges ahead

Transmedics Group Inc (TMDX) delivered strong financial performance in Q1 2023, driven by the success of the TransMedics NOP and consistent growth in liver and heart cases. Despite facing operational challenges and increased expenses, the company remains optimistic about its growth prospects and revenue guidance for 2023. Strategic focus on product availability and infrastructure expansion bodes well for future success.

TransMedics reports record Q2 revenue, eyes transplant logistics expansion

TransMedics Group Inc's Q2 earnings call highlighted robust performance, strategic acquisitions, and ambitious growth targets, underpinning their market position.
While facing challenges in profitability and operational timelines, the company's focus on enhancing logistics and expanding revenue streams signals a promising trajectory.
Investors should monitor TransMedics' execution of growth plans, including the aviation fleet expansion and next-gen lung system integration, for future value creation.

TransMedics reports stellar Q3 results, eyes expansion and efficiency

TransMedics Group Inc's Q3 earnings call highlighted exceptional revenue growth, operational achievements, and strategic acquisitions, positioning the company for continued success.
The company's focus on revenue diversification, operational efficiency, and innovation underscores its commitment to driving growth and improving patient outcomes.
Despite challenges in growth analysis and program limitations, TransMedics remains optimistic about future opportunities and is poised to capitalize on market trends.

Transmedics Group reports robust earnings, eyes growth in transplant services

Transmedics Group Inc (TMDX) delivered strong financial results in Q4 and full-year 2023, showcasing revenue growth and operational profitability, despite margin pressures.
The company's focus on expanding transplant logistics services, addressing concerns, and presenting data analysis at conferences highlights its commitment to growth and innovation.
With strategic initiatives planned for 2024, TransMedics aims to drive market share in heart, liver, and lung transplants, capitalize on growth opportunities, and enhance operational efficiency for sustained success.
Confidence in providing cost-effective transplant logistics and plans for equal contribution from all three organs position TransMedics for future growth and market leadership in the transplant industry.

TransMedics reports robust Q1 earnings, eyes global expansion and innovation

TransMedics Group Inc (TMDX) delivered strong Q1 2024 results, with notable revenue growth and margin improvement, setting the stage for continued expansion and innovation in the transplant industry.
The company's strategic focus on next-gen technology platforms, new clinical programs, and international market expansion positions it well for sustained growth and leadership in the sector.
While facing challenges in margin improvement and market acceptance, TransMedics has the opportunity to leverage its strengths in product innovation and global appeal to drive future success.

Transmedics Group Inc (TMDX) excels in Q2, eyes clinical program growth

Transmedics Group Inc delivered a stellar performance in Q2 2024, marked by robust revenue growth, operational profitability, and positive free cash flow.
The company's strategic initiatives to expand the aviation fleet, launch new clinical programs, and raise revenue guidance demonstrate a focus on innovation and growth.
While facing challenges in program launches and market competition, Transmedics remains well-equipped to leverage opportunities for market expansion and sustained success.

Transmedics reports robust Q3 performance amidst market challenges

Transmedics Group Inc delivered strong financial results in Q3 2024, driven by robust U.S. sales growth and strategic investments in infrastructure and technology.
While facing challenges with declining transplant volumes and margin pressures, the company remains focused on long-term growth initiatives and maintaining operational efficiency.
Opportunities lie in optimizing international sales, exploring new growth avenues, and leveraging innovative technologies to drive future revenue and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANDOVER, Mass., Sept. 7, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its OCS Heart System for use with organs from donors after brain death (DBD).

TransMedics Receives FDA Approval for its OCS Heart System Enabling Broader Utilization of Donor Hearts for Transplantation in the U.S.­

ANDOVER, Mass., Aug. 26, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a virtual fireside chat at the upcoming Morgan Stanley 19th Annual Global Healthcare Conference.

TransMedics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

TransMedics has seen continued progress in the business, mostly on the research front. The pandemic is still halting revenue growth as more approvals and lifting of restrictions might drive growth from here.

TransMedics: Transforming Lives, Potentially Transforming Stock

TransMedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q2 2021 Results - Earnings Call Transcript

ANDOVER, Mass., Aug. 5, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2021.

TransMedics Reports Second Quarter 2021 Financial Results

ANDOVER, Mass., July 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its OCS™ Lung Solution for use in transplants using cold storage techniques.

TransMedics Receives FDA Clearance of OCS Lung Solution for Cold Preservation of Lungs

TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will TransMedics (TMDX) Report Negative Earnings Next Week? What You Should Know

ANDOVER, Mass., July 28, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will participate in a virtual fireside chat at the upcoming Canaccord Genuity 41st Annual Growth Conference.

TransMedics to Participate in the Canaccord Genuity 41st Annual Growth Conference

ANDOVER, Mass., July 22, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter after market close on Thursday, August 5, 2021.

TransMedics to Report Second Quarter 2021 Financial Results on August 5, 2021

The Gastroenterology and Urology Devices Panel of the FDA's Medical Devices Advisory Committee has issued a favorable vote to support the approval of TransMedics Group Inc's (NASDAQ:TMDX) OCS Liver System.  The panel voted 14 to 0 that there is reasonable assurance that the OCS Liver System is effective and 14 to 0 that there is reasonable assurance of the OCS Liver System's safety.

FDA Advisory Committee Gives Thumbs Up To TransMedics' OCS Liver System

ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after review and discussion of TransMedics' clinical evidence from the OCS Liver PROTECT trial, the Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee convened by the U.S. Food and Drug Administration ("FDA") has issued a favorable vote in support of approval of the OCS Liver System.

TransMedics Announces Positive FDA Advisory Committee Vote for the OCS Liver System

Shares of TransMedics Group Inc. were halted on Wednesday in advance of an advisory committee meeting scheduled for the same day by the Food and Drug Administration. The committee is expected to review the company's premarket approval application for an investigational liver treatment device and then vote on whether the FDA should approve the system.

TransMedics Group's stock is halted in advance of FDA committee meeting

ANDOVER, Mass., July 14, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that Nasdaq has halted trading of the company's common stock.

TransMedics Stock Trading Halted Today; FDA Advisory Committee to Review Premarket Approval Application for the OCS Liver System

ANDOVER, Mass., June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that the U.S. Food and Drug Administration ("FDA") has announced the scheduling of a public advisory committee meeting during which it will review information regarding TransMedics' premarket approval application for the OCS Liver System.

TransMedics Announces Scheduling of OCS Liver FDA Advisory Committee Meeting

ANDOVER, Mass., June 8, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced that the complete results of the OCS™ Liver PROTECT Trial ("PROTECT") were presented virtually at the American Transplant Congress on Tuesday June 8 th, 2021.

TransMedics Announces Presentation of OCS Liver PROTECT Trial Results and is Recognized as Winner of The People's Choice Award for Most Impactful Presentation at the American Transplant Congress (ATC 2021)

Cantaloupe, Inc

Nuvation Bio

David Abrams (Trades, Portfolio), the leader of Abrams Capital Management, disclosed his first-quarter portfolio earlier this month.

David Abrams Buys 3 Stocks in 1st Quarter

Transmedics Group, Inc. (TMDX) CEO Waleed Hassanein on Q1 2021 Results - Earnings Call Transcript

Shares of TransMedics Group (NASDAQ:TMDX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 30.95% over the past year to ($0.29), which were in line with the estimate of ($0.29).

Recap: TransMedics Group Q1 Earnings

ANDOVER, Mass., May 4, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2021.

TransMedics Reports First Quarter 2021 Financial Results

TransMedics is looking to disrupt an entire industry and help thousands of transplant patients in the U.S. in the process.

1 Feel-Good Healthcare Stock That Could Turn Your Tax Return Into Riches

ANDOVER, Mass., April 20, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter after market close on Tuesday, May 4, 2021.

TransMedics to Report First Quarter 2021 Financial Results on May 4, 2021

TMDX is a medical device company with a revenue generating stream and upcoming catalysts. Its organ care system is a novel concept that works better than current standards.

TransMedics: Organ Transplant Preservation Technology With Upcoming Catalysts

The FDA Advisory Committee has voted in favor of TransMedics Group Inc (NASDAQ: TMDX) after reviewing clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol (CAP) results, as well as the OCS Heart PROCEED II trial. The panel voted 12 to 5, with one abstaining, the benefits of the OCS Heart System outweigh its risks.

TransMedics Stock Is Trading Higher After FDA Adcom Votes In Favor Of Its OCS Heart System

The stock price of TransMedics Group (NASDAQ: TMDX) increased by over 10% pre-market. This is why it happened.

TransMedics Stock Price Increased Over 10% Pre-Market: Why It Happened

ANDOVER, Mass., April 6, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today that after the review of TransMedics' clinical evidence from the OCS Heart EXPAND trial, the associated Continued Access Protocol ("CAP") results, as well as the OCS Heart PROCEED II trial, the Circulatory Systems Device Advisory Panel convened by the U.S. Food and Drug Administration ("FDA") has issued a favorable vote in support of approval of the OCS Heart System to the FDA's Office of Health Technology 2 (Cardiovascular Devices).

News for Transmedics Group Inc Stock (TMDX)